S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
These 2 carnivore dining stocks gaining on the Ozempic craze
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
This healthcare stock making a buzz with 160% growth
How major US stock indexes fared Monday, 2/26/2024
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
This infrastructure construction stock: Is it ready to pop?
Is Roku worth a second look after the earnings panic selloff?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Is The Trade Desk signaling the rebound of digital advertising?
Domino’s stock or Papa John’s? Follow price action to find out
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
These 2 carnivore dining stocks gaining on the Ozempic craze
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
This healthcare stock making a buzz with 160% growth
How major US stock indexes fared Monday, 2/26/2024
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
This infrastructure construction stock: Is it ready to pop?
Is Roku worth a second look after the earnings panic selloff?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Is The Trade Desk signaling the rebound of digital advertising?
Domino’s stock or Papa John’s? Follow price action to find out
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
These 2 carnivore dining stocks gaining on the Ozempic craze
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
This healthcare stock making a buzz with 160% growth
How major US stock indexes fared Monday, 2/26/2024
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
This infrastructure construction stock: Is it ready to pop?
Is Roku worth a second look after the earnings panic selloff?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Is The Trade Desk signaling the rebound of digital advertising?
Domino’s stock or Papa John’s? Follow price action to find out
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
These 2 carnivore dining stocks gaining on the Ozempic craze
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
This healthcare stock making a buzz with 160% growth
How major US stock indexes fared Monday, 2/26/2024
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
This infrastructure construction stock: Is it ready to pop?
Is Roku worth a second look after the earnings panic selloff?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Is The Trade Desk signaling the rebound of digital advertising?
Domino’s stock or Papa John’s? Follow price action to find out

Nuvalent (NUVL) Competitors

$86.61
-0.65 (-0.74%)
(As of 02/26/2024 ET)

NUVL vs. ALKS, OGN, BPMC, MDGL, PRGO, INSM, MRTX, ACAD, FOLD, and BBIO

Should you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Alkermes (ALKS), Organon & Co. (OGN), Blueprint Medicines (BPMC), Madrigal Pharmaceuticals (MDGL), Perrigo (PRGO), Insmed (INSM), Mirati Therapeutics (MRTX), ACADIA Pharmaceuticals (ACAD), Amicus Therapeutics (FOLD), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical preparations" industry.

Nuvalent vs.

Alkermes (NASDAQ:ALKS) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Alkermes has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.66B3.02$355.76M$2.0714.51
NuvalentN/AN/A-$81.85M-$2.03-42.67

95.2% of Alkermes shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 4.8% of Alkermes shares are held by insiders. Comparatively, 14.8% of Nuvalent shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alkermes received 665 more outperform votes than Nuvalent when rated by MarketBeat users. Likewise, 70.82% of users gave Alkermes an outperform vote while only 65.38% of users gave Nuvalent an outperform vote.

CompanyUnderperformOutperform
AlkermesOutperform Votes
682
70.82%
Underperform Votes
281
29.18%
NuvalentOutperform Votes
17
65.38%
Underperform Votes
9
34.62%

Alkermes has a net margin of 21.39% compared to Alkermes' net margin of 0.00%. Nuvalent's return on equity of 16.10% beat Alkermes' return on equity.

Company Net Margins Return on Equity Return on Assets
Alkermes21.39% 16.10% 9.15%
Nuvalent N/A -26.46%-25.20%

Alkermes currently has a consensus price target of $32.50, suggesting a potential upside of 8.19%. Nuvalent has a consensus price target of $69.50, suggesting a potential downside of 19.76%. Given Nuvalent's higher possible upside, analysts clearly believe Alkermes is more favorable than Nuvalent.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38
Nuvalent
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Alkermes had 7 more articles in the media than Nuvalent. MarketBeat recorded 21 mentions for Alkermes and 14 mentions for Nuvalent. Alkermes' average media sentiment score of 0.61 beat Nuvalent's score of 0.59 indicating that Nuvalent is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alkermes
8 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Nuvalent
3 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alkermes has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.

Summary

Alkermes beats Nuvalent on 11 of the 17 factors compared between the two stocks.


Get Nuvalent News Delivered to You Automatically

Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NUVL vs. The Competition

MetricNuvalentPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$5.42B$7.32B$5.11B$7.46B
Dividend YieldN/A2.81%2.86%3.87%
P/E Ratio-42.6718.42251.2418.42
Price / SalesN/A965.413,417.31179.39
Price / CashN/A18.1425.3925.75
Price / Book9.034.704.574.56
Net Income-$81.85M$163.34M$111.11M$210.58M
7 Day Performance0.46%2.85%1.84%-0.18%
1 Month Performance13.51%10.42%9.71%3.65%
1 Year Performance187.84%4.08%11.75%6.81%

Nuvalent Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALKS
Alkermes
3.2812 of 5 stars
$30.39
-5.6%
$32.50
+6.9%
+10.5%$5.07B$1.66B14.682,280Gap Down
OGN
Organon & Co.
4.9952 of 5 stars
$18.50
-1.1%
$23.33
+26.2%
-31.1%$4.73B$6.26B4.6210,000
BPMC
Blueprint Medicines
0.8057 of 5 stars
$91.25
+1.1%
$80.73
-11.5%
+150.3%$5.59B$249.38M-10.92661Analyst Report
MDGL
Madrigal Pharmaceuticals
4.7785 of 5 stars
$229.71
-1.5%
$304.00
+32.3%
-15.8%$4.53BN/A-11.9492Analyst Downgrade
Analyst Revision
News Coverage
Positive News
Gap Down
PRGO
Perrigo
4.9269 of 5 stars
$32.32
+0.9%
$44.25
+36.9%
-11.3%$4.38B$4.45B646.538,900Dividend Increase
News Coverage
Positive News
INSM
Insmed
3.6445 of 5 stars
$29.21
-1.0%
$44.90
+53.7%
+43.2%$4.22B$280.82M-5.54373Earnings Report
Analyst Revision
MRTX
Mirati Therapeutics
0.3258 of 5 stars
$58.70
-0.2%
$60.00
+2.2%
N/A$4.12B$12.44M-4.80587High Trading Volume
ACAD
ACADIA Pharmaceuticals
4.1914 of 5 stars
$24.85
-1.0%
$36.26
+45.9%
+36.9%$4.08B$517.23M-27.01580
FOLD
Amicus Therapeutics
2.9841 of 5 stars
$13.70
-0.4%
$17.20
+25.5%
+6.6%$4.02B$329.23M-23.22484Upcoming Earnings
BBIO
BridgeBio Pharma
4.4237 of 5 stars
$35.95
-3.4%
$42.00
+16.8%
+199.3%$6.25B$77.65M-9.22392Earnings Report

Related Companies and Tools

This page (NASDAQ:NUVL) was last updated on 2/27/2024 by MarketBeat.com Staff